Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Slides:

Advertisements

Similar presentations

Baptist Health System General Surgery Residency Program

Advertisements

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Oncotype DX® Breast Cancer Assay Clinical Data Review

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.

Breast Cancer in Pregnancy

Role of Nodal Irradiation in Breast Cancer

An update for Illinois Nurses Elizabeth A. Peralta, MD The Breast Center at SIU Springfield, IL May 2011.

Giuliano Pre-SSO mins ASCO Z mins

Ductal Carcinoma In Situ: Where Are We Now?

Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine.

Sentinel Lymph Node Dissection (SND)

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Margins: less is just as good

Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Ductal Carcinoma in situ

Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.

Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

Dilemma in management of DCIS

Tang G et al. Proc SABCS 2010;Abstract S4-9.

Ductal Carcinoma In Situ (DCIS)

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.

Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.

Management of DCIS KWH Experience Dr. Carmen Ho.

Radiation Breast Oncology Highlights of SABC 2006 Alison Bevan, MD PhD UCSF Radiation Oncology January, 2007.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2013 – December 31, 2013 Compiled by Uzma Nazim, M.D.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

18th Annual Perspectives in Breast Cancer

DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2014 – December 31, 2014 Compiled by L.Day, RN BSN CCM CCRP OCN 1.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

CALGB 9343 Comparison of Lumpectomy Plus Tamoxifen With and Without Irradiation in Women 70 or Older with Clinical Stage I, ER+ Breast Carcinoma Kevin.

Refining Radiotherapy for Early Breast Cancer: The Challenges. David Dodwell Radiotherapy in Practice Sheffield Hallam University October 2010.

Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.

BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.

The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Breast Surgery in Delhi Breast Cancer Epidemiology Halsted Theory Radical Mastectomy Fisher Theory Modified Radical Mastectomy Goals of Breast Conservation.

Nicolas Ajkay, MD, FACS Assistant Professor of Surgery

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB (HER2-Positive) and CALGB.

Ari Brooks, MD Cancer Surgeon, Big Data End User

Copyright © 2013 American Medical Association. All rights reserved.

Dr Amit Gupta Associate Professor Dept Of Surgery

The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy C.

Definitive Analysis of the Primary Outcomes

THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.

Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT

Treatment Overview: The Multidisciplinary Team

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient.

Presentation transcript:

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard Medical School Surgeon The Newton-Wellesley Hospital Breast Center Is Post-Lumpectomy Radiation Necessary in Older Patients?

1.9 cm, ER+, clinical N0 Cancer Lumpectomy Plus Radiation/Boost Tamoxifen Sentinel Node Chemotherapy BRCA testing

1.9 cm, ER+, clinical N0 Cancer Lumpectomy Plus Radiation/Boost Tamoxifen Sentinel Node Chemotherapy BRCA testing Lumpectomy Plus Radiation/Boost Tamoxifen/AI Sentinel Node Chemotherapy BRCA testing

CALGB 9343 Comparison of Lumpectomy Plus Tamoxifen With and Without Irradiation in Women 70 or Older with Clinical Stage I, ER+ Breast Carcinoma Kevin S. Hughes, Lauren A. Schnaper, Constance Cirrincione, Donald Berry, Beryl McCormick, Hyman B. Muss, Clifford Hudis, Eric Winer, Barbara L. Smith Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group

CALGB 9343 ELIGIBILITY Age  70 ELIGIBILITY Age  70Clinically Node Negative Lumpectomy, Negative Margin Tumor size  2 cm Node Negative Lumpectomy, Negative Margin Tumor size  2 cm ER Positive or Indeterminate STRATIFICATION Age < 75  75 Axillary Dissection Yes No RadiationTamoxifen Tamoxifen RANDOMIZERANDOMIZERANDOMIZERANDOMIZE

CALGB 9343 Opened July 15, 1994 Closed February 26, patients –Eligible 631 –Ineligible 5 –Canceled/Never treated 11 Median follow-up 12 years

Patient characteristics RT+Tam Tam Total treated Age > (56%)172 (54%) ER Positive308 (97%)310 (97%) Size < 2cm295 (93%)296 (93%) No Ax dissection 200 (63%)203 (64%)

IBTR (Ipsilateral Breast Tumor Recurrence) 91% 98%

Ipsilateral cancer risk 40 and under RT 70 above no RT LCIS

Radiation decreases local recurrence by ~7% Does it do anything else?

No RT Mastectomy Lumpectomy IBTR 27 RT IBTR

Actuarial survival for given ages at entry D. Berry 8/28/11

Ultimate Outcome

Breast Recurrence Less Ultimate Mastectomy Same Second primary cancer Same Distant metastasis Same Death Same Death Other CausesSame Death from breast cancerSame 22 women With modern margins and AI’s, RT will likely have even less benefit CONCLUSION: In older women, the benefits of radiation after lumpectomy are small